{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969772",
  "id": "02969772",
  "pages": 37,
  "price_sensitive": true,
  "date": "20250716",
  "time": "1040",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250716/pdf/06lv9wd986qnc6.pdf",
  "summary": "**Capital Raising Announcement Summary:**  \n\n- **Structure:** Placement (A$22.5m) + Share Purchase Plan (SPP, A$15m) for total **A$37.5m** at **A$0.33/share** (19.6% discount to 5-day VWAP).  \n- **Attaching Options:** 3 options per 4 new shares (exercise price A$0.43, expiry 30 Mar 2026). Piggyback options (A$0.86, expiry 30 Jun 2028) upon exercise.  \n- **Key Dates:**  \n  - Record date for SPP: 15 Jul 2025.  \n  - SPP opens: 24 Jul 2025; closes: 18 Aug 2025.  \n  - EGM for approvals: ~20 Aug 2025.  \n- **Pro-Forma Cash:** A$64m post-raise, funding runway to **2H 2026** (extendable to mid-2027 if options exercised).  \n\n**Operational Highlights (Azer-cel Program):**  \n- **Phase 1b Trial Data:** 75% ORR (9/12 patients), 55% CR (6/11 evaluable), durability >450 days in relapsed DLBCL.  \n- **Regulatory Pathway:** FDA Fast Track granted; **End-of-Phase 1b meeting targeted Q4 2025** to discuss registrational Phase 2 trial (single-arm, rare lymphomas).  \n- **Market Opportunity:** **US$2bn+** in CAR-T na\u00efve/relapsed lymphomas.  \n\n**Risks:** Clinical trial, regulatory, and commercialization risks noted (no approved products yet).  \n\n**Note:** Excludes non-material operational details, disclaimers, and pipeline updates (onCARlytics/CF33).",
  "usage": {
    "prompt_tokens": 12673,
    "completion_tokens": 394,
    "total_tokens": 13067,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T00:57:58.663443"
}